fluorodeoxyglucose f18 has been researched along with Agyria in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, YK; Huang, BK | 1 |
| Amamoto, M; Azuma, M; Hattori, S; Hayasaka, K; Hirotsune, S; Kataoka, Y; Kato, M; Kumamoto, K; Miyakawa, T; Oka, Y; Sato, M; Takao, K; Tamura, Y; Toba, S; Tominaga, K; Wanibuchi, H; Wynshaw-Boris, A; Yamada, M | 1 |
2 other study(ies) available for fluorodeoxyglucose f18 and Agyria
| Article | Year |
|---|---|
Epileptogenic pachygyria demonstrating on FDG PET.
Topics: Child, Preschool; Epilepsy; Fluorodeoxyglucose F18; Humans; Lissencephaly; Male; Positron-Emission Tomography; Radiopharmaceuticals | 2012 |
Post-natal treatment by a blood-brain-barrier permeable calpain inhibitor, SNJ1945 rescued defective function in lissencephaly.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Administration, Oral; Animals; Blood-Brain Barrier; Calpain; Carbamates; Cell Line; Fluorodeoxyglucose F18; Glycoproteins; Humans; Lissencephaly; Male; Mice; Microtubule-Associated Proteins; Motor Activity; Nerve Growth Factor; Neurons; Positron-Emission Tomography; Receptors, GABA | 2013 |